Video Series

Dr Garfall, MD, provides insights following results derived from the MajesTEC-1 study.

Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.

Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson.

Dr Lipson continues his discussion as he highlights significant results from the NADINA trial.

Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.

Key considerations for transfusion requirements in patients with PNH are discussed by key opinion leaders.

Dr Haumschild and a panel of medical experts underscore financial considerations in PNH treatment.

The panel delves into the most challenging symptoms of atopic dermatitis (AD), maps out the patient journey, and highlights crucial factors in effectively managing itch and other AD-related symptoms.

Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, provide insights on the differences between therapies that require continuous use versus those that can be intermittently used for atopic dermatitis (AD), explore the potential of combination therapy, and discuss optimal efficacy and duration of therapy regimens to maximize patient outcomes.

Dr. Cannon leads a conversation navigating the impact of payer coverage on the uptake of biosimilars.

The panel discusses the impact of interchangeability and value of switching studies in biosimilar adoption.

A panel of experts discuss sequencing considerations with CDK4/6.

Dr. Dempsey discusses key results from the NATALEE and MonarchE trials.

William J. Gradishar, MD, highlights the inclusion of abemaciclib in the NCCN Guidelines for select high-risk early-stage breast cancer patients, anticipates the potential for ribociclib to secure a similar guideline position, and emphasizes the importance of monitoring treatment response.

A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores patient and disease-related factors that guide the decision to incorporate CDK4/6 inhibitors in this context.

Dr Haumschild continues leading a discussion surrounding potential treatment advancements in the PNH landscape.

Economic impacts on patients receiving treatment for PNH and a conversation surrounding treatment adherence are discussed by key opinion leaders.

Medical experts discuss the long-term consequences of extended use of topical corticosteroids or calcineurin inhibitors in atopic dermatitis (AD) patients and recommend appropriate monitoring strategies.

The panel examines the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD management.

Dr Humphreys drives a conversation scoping the biosimilar landscape and available treatment options.

Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.

Experts on chronic spontaneous urticaria outline the hallmark symptoms most associated with the disease and how they fluctuate with time.

Alfred L. Garfall, MD, opens a discussion underscoring the unmet needs in multiple myeloma.

A panel of experts describe the pathophysiology of chronic spontaneous urticaria.

Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, and Chad Cannon, PharmD, BCCCP, open a panel discussion highlighting specialty biologics and navigating challenges for biosimilar uptake.

Key opinion leaders provide insight to providing biomarker testing within and beyond guideline recommendations.

Mark Socinski, MD, introduces a panel of medical experts as they kick off a discussion surrounding biomarker testing and guideline recommendations in the metastatic non-small cell lung cancer treatment landscape.

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing unmet needs at ASCO 2024.

Results from the monarchE trial are analyzed by Hope Rugo, MD, and Joyce O'Shaughnessy, MD.